Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program

Malcolm A. Smith, Christopher L. Morton, E. Anders Kolb, Richard Gorlick, Stephen T. Keir, Hernan Carol, Richard Lock, Min H. Kang, C. Patrick Reynolds, John M. Maris, Amy E. Watkins, Peter J. Houghton

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that exclusively targets and activates tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). It was tested in vitro at concentrations from 0.01 to 100 μg/ml and in vivo at a dose of 10 mg/kg administered intraperitoneally using a twice-weekly schedule. Mapatumumab demonstrated limited activity against the 23 cell lines of the PPTP in vitro panel with no lines achieving 50% growth inhibition. Mapatumumab induced significant differences in event-free survival distribution compared to controls in 9 of 37 evaluable solid tumor xenografts tested, but in none of the 8 ALL xenografts.

Original languageEnglish (US)
Pages (from-to)307-310
Number of pages4
JournalPediatric Blood and Cancer
Issue number2
StatePublished - Feb 2010
Externally publishedYes


  • Developmental therapeutics
  • Mapatumumab
  • Preclinical testing

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program'. Together they form a unique fingerprint.

Cite this